# A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

> **NCT03747575** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** MSTT1041A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03747575
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2020-03-11
- **Final completion:** 2020-05-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747575, "A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03747575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*